Axon Enterprise, Inc $AXON Shares Sold by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. trimmed its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 92.5% during the third quarter, HoldingsChannel reports. The firm owned 292 shares of the biotechnology company’s stock after selling 3,581 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Axon Enterprise were worth $210,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Assenagon Asset Management S.A. increased its holdings in shares of Axon Enterprise by 5.6% in the third quarter. Assenagon Asset Management S.A. now owns 131,862 shares of the biotechnology company’s stock valued at $94,629,000 after purchasing an additional 7,012 shares during the last quarter. Sanders Morris Harris LLC purchased a new stake in Axon Enterprise in the 3rd quarter valued at $319,000. Oak Thistle LLC acquired a new stake in shares of Axon Enterprise in the 3rd quarter worth $1,127,000. Jackson Wealth Management LLC acquired a new stake in shares of Axon Enterprise in the 3rd quarter worth $485,000. Finally, GAMMA Investing LLC boosted its position in shares of Axon Enterprise by 5.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,821 shares of the biotechnology company’s stock valued at $1,307,000 after acquiring an additional 95 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $555.06 on Wednesday. The company’s 50 day simple moving average is $617.36 and its 200-day simple moving average is $711.31. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91. The company has a market capitalization of $43.80 billion, a price-to-earnings ratio of 175.65, a price-to-earnings-growth ratio of 126.73 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The business’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.45 EPS. As a group, equities research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the completion of the transaction, the president directly owned 249,502 shares in the company, valued at $137,874,805.20. This trade represents a 7.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jeffrey C. Kunins sold 1,797 shares of Axon Enterprise stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total value of $968,996.31. Following the completion of the transaction, the insider directly owned 83,485 shares of the company’s stock, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 64,406 shares of company stock valued at $38,521,038. Corporate insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

AXON has been the subject of several recent analyst reports. Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. The Goldman Sachs Group reduced their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. UBS Group decreased their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $802.71.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.